Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Prepaid Assets (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Prepaid Assets for 15 consecutive years, with $503147.0 as the latest value for Q4 2025.

  • On a quarterly basis, Prepaid Assets rose 2.01% to $503147.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $503147.0, a 2.01% increase, with the full-year FY2025 number at $223759.0, down 13.87% from a year prior.
  • Prepaid Assets was $503147.0 for Q4 2025 at PharmaCyte Biotech, up from $238180.0 in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $549094.0 in Q3 2021 to a low of $28148.0 in Q3 2022.
  • A 5-year average of $231147.0 and a median of $230969.5 in 2025 define the central range for Prepaid Assets.
  • Biggest YoY gain for Prepaid Assets was 317.41% in 2022; the steepest drop was 94.87% in 2022.
  • PharmaCyte Biotech's Prepaid Assets stood at $241799.0 in 2021, then increased by 6.21% to $256808.0 in 2022, then rose by 25.85% to $323189.0 in 2023, then soared by 52.61% to $493213.0 in 2024, then rose by 2.01% to $503147.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Prepaid Assets are $503147.0 (Q4 2025), $238180.0 (Q3 2025), and $223759.0 (Q2 2025).